BiomX Inc. (PHGE)
AMEX$0.595-0.01 (-1.66%)
Market Cap
$15.07M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
776 of 924
Rank in Industry
436 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PHGE Insider Trading Activity
PHGE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 1 | 50 |
Sells | $9,280 | 1 | 50 |
Related Transactions
| OrbiMed Israel BioFund GP Limited Partnership | 10 percent owner | 1 | $0 | 1 | $9,280 | $-9,280 |
About BiomX Inc.
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a …
Insider Activity of BiomX Inc.
Over the last 12 months, insiders at BiomX Inc. have bought $0 and sold $9,280 worth of BiomX Inc. stock.
On average, over the past 5 years, insiders at BiomX Inc. have bought $25,823 and sold $110,480 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,327 shares for transaction amount of $0 was made by OrbiMed Israel BioFund GP Limited Partnership (10 percent owner) on 2024‑03‑15.
List of Insider Buy and Sell Transactions, BiomX Inc.
| 2024-05-15 | Sale | OrbiMed Israel BioFund GP Limited Partnership | 10 percent owner | 24,344 0.0486% | $0.38 | $9,280 | -72.54% | |
| 2024-03-15 | OrbiMed Israel BioFund GP Limited Partnership | 10 percent owner | 4,327 – | $0 | $0 | -70.63% | ||
| 2023-11-29 | Sale | Oron Assaf | Chief Business Officer | 10,914 0.0292% | $0.37 | $4,072 | -19.00% | |
| 2023-05-22 | Oron Assaf | Chief Business Officer | 3,192 0.01% | $0.27 | $872 | +28.68% | ||
| 2023-05-19 | Oron Assaf | Chief Business Officer | 6,521 0.0204% | $0.28 | $1,832 | +25.00% | ||
| 2023-05-18 | Oron Assaf | Chief Business Officer | 1,201 0.0037% | $0.27 | $328 | +26.35% | ||
| 2023-02-27 | OrbiMed Israel BioFund GP Limited Partnership | 10 percent owner | 348,000 0.7935% | $0.24 | $85,260 | -12.50% | ||
| 2022-11-04 | Sale | Ugwumba Chidozie | director | 1,501 0.005% | $0.38 | $567 | -12.50% | |
| 2022-11-03 | Sale | Ugwumba Chidozie | director | 2,000 0.0065% | $0.37 | $732 | -12.37% | |
| 2022-11-02 | Sale | Ugwumba Chidozie | director | 2,416 0.0081% | $0.36 | $867 | -7.76% | |
| 2022-11-01 | Sale | Ugwumba Chidozie | director | 1,300 0.0043% | $0.36 | $473 | -10.00% | |
| 2022-10-31 | Sale | Ugwumba Chidozie | director | 3,300 0.0114% | $0.37 | $1,224 | -6.94% | |
| 2022-10-28 | Sale | Ugwumba Chidozie | director | 1,526 0.0048% | $0.36 | $543 | -10.88% | |
| 2022-10-27 | Sale | Ugwumba Chidozie | director | 1,505 0.0051% | $0.36 | $548 | -5.87% | |
| 2022-10-26 | Sale | Ugwumba Chidozie | director | 12,500 0.0386% | $0.35 | $4,325 | -10.13% | |
| 2022-10-25 | Sale | Ugwumba Chidozie | director | 3,072 0.0102% | $0.36 | $1,121 | -7.86% | |
| 2022-10-24 | Sale | Ugwumba Chidozie | director | 5,900 0.0191% | $0.35 | $2,059 | -5.82% | |
| 2022-10-21 | Sale | Ugwumba Chidozie | director | 5,400 0.0177% | $0.37 | $1,998 | -9.81% | |
| 2022-10-20 | Sale | Ugwumba Chidozie | director | 6,636 0.0219% | $0.37 | $2,482 | -10.53% | |
| 2022-10-19 | Sale | Ugwumba Chidozie | director | 4,501 0.0142% | $0.37 | $1,652 | -12.37% |
Total: 89
*Gray background shows transactions not older than one year
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Insider Historical Profitability
<0.0001%
| OrbiMed Israel BioFund GP Limited Partnership | 10 percent owner | 13773653 55.1032% | $8.3M | 9 | 1 | <0.0001% |
| Chimovits Erez | director, 10 percent owner | 2313489 9.2554% | $1.39M | 7 | 0 | <0.0001% |
| GROSSMAN JONAS | director | 372717 1.4911% | $224,673.81 | 4 | 0 | <0.0001% |
| Amusa Gbolahan | director | 262871 1.0516% | $158,458.64 | 1 | 0 | |
| Wolfson Marina | SVP of Finance & Operations | 3750 0.015% | $2,260.50 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,900,811 | 57 | -24.79% | $14.9M | |
$85,897,100 | 36 | 2.47% | $16.75M | |
$4,368,362 | 28 | -22.35% | $13.81M | |
BiomX Inc. (PHGE) | $550,893 | 22 | -22.12% | $15.07M |
$206,127 | 21 | -29.00% | $16.64M |
PHGE Institutional Investors: Active Positions
| Increased Positions | 8 | +33.33% | 2M | +21.79% |
| Decreased Positions | 9 | -37.5% | 972,544 | -10.74% |
| New Positions | 7 | New | 2M | New |
| Sold Out Positions | 5 | Sold Out | 546,506 | Sold Out |
| Total Postitions | 23 | -4.17% | 10M | +11.05% |
PHGE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Orbimed Advisors Llc | $1,116.00 | 9.93% | 1.79M | 0 | 0% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $1,115.00 | 9.93% | 1.79M | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $1,080.00 | 9.61% | 1.73M | 0 | 0% | 2024-12-31 |
| Ikarian Capital, Llc | $557.00 | 4.96% | 892,976 | -24 | <0.01% | 2024-12-31 |
| Aigh Capital Management Llc | $540.00 | 4.81% | 865,400 | 0 | 0% | 2024-12-31 |
| Alyeska Investment Group, L.P. | $540.00 | 4.81% | 865,400 | +865,400 | New | 2024-12-31 |
| Allostery Investments Lp | $402.00 | 3.58% | 643,833 | +643,833 | New | 2024-12-31 |
| Jpmorgan Chase & Co | $268.00 | 2.39% | 429,990 | +429,990 | New | 2024-12-31 |
| Dafna Capital Management Llc | $250.00 | 2.23% | 401,136 | 0 | 0% | 2024-12-31 |
| Heights Capital Management, Inc | $161.00 | 1.44% | 258,492 | -330,535 | -56.12% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.